Medtronic Announces End To Shareholder Infuse Case
Executive Summary
A long-running shareholder case against Medtronic has come to an end after the US Supreme Court refused to hear the plaintiff's appeal.
You may also be interested in...
Medtronic Agrees To Settle Infuse Shareholder Suit
Device manufacturer Medtronic has offered to pay $43m to resolve a lawsuit brought by shareholders. The suit, filed in 2013, claimed that the company defrauded investors via deceptive marketing for its Infuse bone graft product.
Medtronic Expects Settlements Of Infuse Suits
The company said in a US SEC filing that it’s reached agreements to settle almost 6,000 outstanding patient injury suits tied to the spine device. Terms of the settlements weren't disclosed.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.